OnKure Therapeutics (OKUR) grants 22,350 options to board director Grey

Rhea-AI Filing Summary

OnKure Therapeutics director Michael G. Grey received a grant of 22,350 stock options to purchase Class A common stock at an exercise price of $4.14 per share. All options vest on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, subject to continued service, and expire on August 6, 2036. Following this grant, he holds 22,350 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GREY MICHAEL G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	22,350	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,350 shares (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Key Figures

Options granted: 22,350 options Exercise price: $4.14 per share Expiration date: August 6, 2036 +3 more

6 metrics

Options granted 22,350 options Stock Option (right to buy) grant to director on 2026-08-07

Exercise price $4.14 per share Conversion or exercise price for the granted stock options

Expiration date August 6, 2036 Option term for the 22,350 stock options

Underlying shares 22,350 shares Class A common stock underlying the granted options

Post-grant holdings 22,350 options Total stock options held directly after the reported transaction

Vesting date June 4, 2027 Cliff vesting, or earlier day before the next annual stockholder meeting

Key Terms

Stock Option (right to buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion or exercise price of $4.1400 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100% of the shares subject to the option will vest on the earlier of June 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders"

FAQ

What equity award did OnKure Therapeutics (OKUR) director Michael G. Grey receive?

Michael G. Grey received a grant of 22,350 stock options for OnKure Therapeutics Class A common stock, with an exercise price of $4.14 per share, expiring on August 6, 2036.

When do Michael G. Grey’s new OnKure (OKUR) stock options vest?

The 22,350 stock options will vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual stockholder meeting, assuming he continues as a service provider through that date.

What is the exercise price of the new OnKure (OKUR) stock options granted to Michael G. Grey?

The granted stock options have an exercise price of $4.14 per share. They cover 22,350 underlying Class A common shares and expire on August 6, 2036, providing long-dated equity-based compensation.

How many OnKure (OKUR) options does Michael G. Grey hold after this transaction?

After this award, Michael G. Grey directly holds 22,350 stock options for OnKure Therapeutics. These options relate to 22,350 underlying Class A common shares, all subject to a single cliff vesting event.

Is Michael G. Grey’s OnKure (OKUR) option grant part of a 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not reference any trading plan, indicating this option grant is not reported as pursuant to a 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 04:36 PM Accepted by SEC EDGAR 08/11/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GREY MICHAEL G

(Last) (First) (Middle)

C/O ONKURE THERAPEUTICS, INC.

6707 WINCHESTERR CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.14	08/07/2026		A		22,350		(1)	08/06/2036	Class A Common Stock	22,350	$0	22,350	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Rogan Nunn, by power of attorney	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)